Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAAA | Q02083 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 3/20 | 0.52 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.48 |
| ▸ | HTR2C | P28335 | 1/20 | 0.46 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.44 |
| ▸ | RAD52 | P43351 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | FAAH | O00519 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | ACHE | P22303 | 5/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31584710 | 1.00 | NAAA (0.52) | NAAATSHREPHX1HTR2CHCAR2 | |
| SCHEMBL7782942 | 1.00 | NAAA (0.52) | NAAATSHREPHX1HTR2CHCAR2 | |
| SCHEMBL31584796 | 1.00 | NAAA (0.52) | NAAATSHREPHX1HTR2CHCAR2 | |
| SCHEMBL31584462 | 1.00 | NAAA (0.52) | NAAATSHREPHX1HTR2CHCAR2 | |
| SCHEMBL18672810 | 1.00 | NAAA (0.52) | NAAATSHREPHX1HTR2CHCAR2 | |
| SCHEMBL2214927 | 1.00 | NAAA (0.52) | NAAATSHREPHX1HTR2CHCAR2 | |
| SCHEMBL7781605 | 1.00 | NAAA (0.52) | NAAATSHREPHX1HTR2CHCAR2 | |
| SCHEMBL7782136 | 1.00 | NAAA (0.52) | NAAATSHREPHX1HTR2CHCAR2 | |
| SCHEMBL7782139 | 1.00 | NAAA (0.52) | NAAATSHREPHX1HTR2CHCAR2 | |
| SCHEMBL7782944 | 1.00 | NAAA (0.52) | NAAATSHREPHX1HTR2CHCAR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113677337-B | Cationic compositions based on self-neutralizing amino acids | 伊诺莱克斯投资公司 | 2025-05-23 | — | — | CN | claimed |
| US-10905683-B2 | Compositions and uses of amidine derivatives | BIOCRYST PHARMACEUTICALS, INC. (US) | 2021-02-02 | — | — | US | disclosed |
| US-20170266172-A1 | Compositions and Uses of Amidine Derivatives | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2017-09-21 | — | — | US | disclosed |
| US-20130245246-A1 | POLYSACCHARIDES COMPRISING CARBOXYL FUNCTIONAL GROUPS SUBSTITUTED BY A HYDROPHOBIC ALCOHOL DERIVATIVE | ADOCIA (FR) | 2013-09-19 | — | — | US | disclosed |
| US-20110178011-A1 | Polysaccharide/BMP complexes which are soluble at physiological pH | ADOCIA (FR) | 2011-07-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130245246-A1 | POLYSACCHARIDES COMPRISING CARBOXYL FUNCTIONAL GROUPS SUBSTITUTED BY A HYDROPHOBIC ALCOHOL DERIVATIVE | CD44, B3GAT3, UGCG | NAAA 747/4885TSHR 1591/4885EPHX1 3629/4885 |
| US-10905683-B2 | Compositions and uses of amidine derivatives | HRH3, HRH2, HRH1 | NAAA 197/4885TSHR 1832/4885EPHX1 208/4885 |
| US-20170266172-A1 | Compositions and Uses of Amidine Derivatives | HRH3, HRH2, HRH1 | NAAA 197/4885TSHR 1832/4885EPHX1 208/4885 |
| US-20110178011-A1 | Polysaccharide/BMP complexes which are soluble at physiological pH | BMP1, BMP2, BMP6 | NAAA 3580/4885TSHR 2272/4885EPHX1 3942/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.